Helix enters DTC game with broad whole exome sequencing platform

by | Jan 4, 2021

Helix made headlines when they announced authorization from the U.S. Food & Drug Administration (FDA) for a whole exome sequencing platform, called the Helix Laboratory Platform. In the same breath, they also announced they obtained 510(k) clearance for their new Helix Genetic Health Risk App for Late-onset Alzheimer’s Disease, a direct-to-consumer (DTC) genetic health risk (GHR) test.

Humans have about 20,000 genes. They are organized into subunits called exons (the protein-coding regions) and introns (the non-coding regions). All of the exons together are known as the exome – this is where most DNA variants associated with diseases will be found. Whole exome sequencing is a broad analysis which looks for variants in the protein-coding regions of DNA. 

With this FDA marketing authorization, Helix joins well-known DTC genetic testing companies 23andMe and Ancestry.com, who hold the prior FDA authorizations (see a list in our December 2020 post).

Monumentally, it is the first-ever FDA authorization for a broad, DNA sequencing device that is intended for DTC use.  

An innovative approach 

Helix applied for their two FDA authorizations simultaneously, but separately, streamlining both applications and with future test development in mind. Here’s how.

Background  

In the US, the marketing of most DTC genetic tests is regulated by the FDA. If the test is the first-of-its-kind, it is reviewed through the de novo premarket review pathway. If a similar genetic test already exists, applicants submit a 510(k) to demonstrate that their device is substantially equivalent to a previously approved device. Exceptions include carrier screening tests, low risk general wellness tests, and ancestry tests

The FDA assesses, analytical validity, clinical validity, claims made by the company, and comprehension of test materials through user comprehension studies.

The Helix Laboratory Platform

The Helix Laboratory Platform (HLP) was submitted as a data generation tool only, with no clinical or interpretation component.  It will only be offered to consumers when paired with a data interpretation tool that has received its own approval. As the first genetic testing device to be considered for FDA authorization in this way (data generation only), the HLP was submitted as a De Novo Classification Request. This prompted the development of a new regulation – a Whole Exome Sequencing Constituent Device (21 CFR 866.6000).

The submission focused on the accuracy and reproducibility of the genetic data that was generated. FDA marketing authorization for the HLP was granted in December 2020 (DEN190035).

The Helix Genetic Health Risk App for Late-onset Alzheimer’s Disease

There is no one gene that directly causes late-onset (>65 years of age) Alzheimer’s disease, however the high-risk variant (e4) in the APOE gene is a known risk-factor for the disease. Age, family history, other genetic factors, and lifestyle also impact our risk for the condition.

Using the 510(k) submission process, Helix applied for approval to market the Helix Genetic Health Risk App (HRA) for Late-onset Alzheimer’s Disease. They followed the 23andMe predicate under regulation 21 CFR 866.5950 – Genetic Health Risk Assessment System. The HRA serves as a data interpretation tool to be used only with the HLP. The test looks at three common variants in the APOE gene (e2, e3, e4) and reports on a person’s risk (increased or decreased) of developing late-onset Alzheimer’s based on the findings.

In their submission, Helix demonstrated their device was substantially equivalent to the predicate, 23andMe’s PGS Genetic Health Risk Report for Late-onset Alzheimer’s Disease (DEN160026, K192073).

A pioneering step forward

With these authorizations, Helix and their partners will be able to develop future tests (such as for cancer or cardiac conditions) that when paired with the HLP are poised to obtain FDA clearance more efficiently.  

FDA authorization of a WES platform is ground-breaking for the genomics field; it represents another step forward in increasing access to genetic health information and raises the importance of work to ensure that test results are communicated effectively to consumers and healthcare providers alike.

For a deeper dive into recent FDA activity, see Decoding FDA DTC Policy in the Genetic Testing Space.